Livalo is a brand-name medication that contains pitavastatin as its active component. It belongs to the cholesterol-lowering class of drugs known as statins (HMG-CoA reductase inhibitors). Livalo is supplied as a pill in strengths of 1 mg, 2 mg, and 4 mg. In Hong Kong, it is a prescription-only product regulated by the Hong Kong Department of Health, which aligns its standards with those of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Pitavastatin blocks the enzyme HMG-CoA reductase, a key catalyst in the liver’s synthesis of cholesterol. By inhibiting this enzyme, the medication reduces the production of low-density lipoprotein (LDL) cholesterol-the “bad” cholesterol that contributes to plaque formation in arteries. The reduction in LDL allows the liver to increase the uptake of circulating LDL particles, further lowering blood cholesterol levels. Typical onset of cholesterol-lowering effect occurs within 2 weeks, with peak effect reached after about 4 weeks of consistent therapy. Pitavastatin is well absorbed after oral administration, undergoes minimal metabolism via CYP2C9 and CYP2C8 pathways, and is primarily excreted unchanged in the bile.
These indications are approved by major regulatory agencies, including the FDA and EMA, and are recognized by the Hong Kong Department of Health for patients who require an additional or alternative statin therapy.
Note: Patients should always provide a complete medication list, including over-the-counter products and herbal supplements, to their healthcare provider before starting Livalo.
This article provides educational information about Livalo and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Co-administration of multiple statins is generally not recommended due to an increased risk of muscle toxicity. If a combination therapy is considered (e.g., adding ezetimibe), a healthcare professional will evaluate the benefit-risk balance and adjust doses accordingly.
Statins, including pitavastatin, have been associated with modest increases in blood glucose in some patients. Individuals with pre-diabetes should have their glucose levels monitored periodically while on therapy.
Livalo tablets are typically round, film-coated, and may bear imprint codes such as “PIT-1”, “PIT-2”, or “PIT-4” corresponding to the 1 mg, 2 mg, and 4 mg strengths, respectively. Appearance can vary by market.
When traveling, keep the medication in its original container with the prescription label attached. Carry enough supply for the entire trip and be prepared to show documentation at airport security if asked.
Statins are not prohibited substances under the World Anti-Doping Agency (WADA) code. However, athletes should disclose all medications to their governing body to avoid inadvertent violations.
All statins share the same primary mechanism of HMG-CoA reductase inhibition. Pitavastatin has a relatively long half-life and may offer a lower potential for drug-drug interactions via CYP pathways compared with some other statins, but individual response varies.
Livalo is contraindicated in active liver disease. Patients with a history of resolved liver conditions should have liver enzymes checked before initiating therapy and be monitored regularly.
Statins are contraindicated during pregnancy because cholesterol is essential for fetal development. Women planning to become pregnant should discontinue the medication under medical supervision.
Take the missed dose as soon as you remember, provided it is still the same day. If the next scheduled dose is approaching, skip the missed dose and resume the regular schedule. Do not double the dose.
Generic pitavastatin contains the same active ingredient, strength, and dosage form as Livalo but may differ in inactive excipients, imprint, or packaging. Therapeutic efficacy and safety are expected to be equivalent when approved by regulatory authorities.
